Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer

Prostate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors su...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammad Esfini Farahani, Yanquan Zhang, Amos Olalekan Akinyemi, Fatemeh Seilani, Md Rakibul Alam, Xiaoqi Liu
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/7/1642
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849407691840028672
author Mohammad Esfini Farahani
Yanquan Zhang
Amos Olalekan Akinyemi
Fatemeh Seilani
Md Rakibul Alam
Xiaoqi Liu
author_facet Mohammad Esfini Farahani
Yanquan Zhang
Amos Olalekan Akinyemi
Fatemeh Seilani
Md Rakibul Alam
Xiaoqi Liu
author_sort Mohammad Esfini Farahani
collection DOAJ
description Prostate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors such as Octamer Binding Factor 4 (OCT4)—plays a crucial role in therapeutic resistance and disease progression. OCT4, in coordination with SOX2 and NANOG, acts as a master regulator of stemness and is frequently upregulated in prostate cancer stem cells (PCSCs). This upregulation contributes to tumor initiation, metastasis, and resistance to both androgen deprivation therapy (ADT) and chemotherapy. In this review, we explore the role of OCT4 in mediating lineage plasticity in prostate cancer, with particular emphasis on its involvement in treatment resistance and neuroendocrine differentiation. We also examine therapeutic strategies aimed at targeting OCT4 directly, such as microRNA-mediated suppression, small-molecule inhibitors, and suicide gene therapy, as well as indirect approaches that modulate OCT4 expression via FGFR and NF-κB signaling pathways. While these strategies offer promising avenues, challenges such as adaptive resistance and the intricate signaling networks within PCSCs remain significant hurdles. A deeper understanding of the molecular mechanisms underlying OCT4-driven plasticity may pave the way for novel therapeutic approaches and improved outcomes in advanced prostate cancer.
format Article
id doaj-art-af5b8097ff714bb8871dfa59a96b6530
institution Kabale University
issn 2227-9059
language English
publishDate 2025-07-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-af5b8097ff714bb8871dfa59a96b65302025-08-20T03:35:58ZengMDPI AGBiomedicines2227-90592025-07-01137164210.3390/biomedicines13071642Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate CancerMohammad Esfini Farahani0Yanquan Zhang1Amos Olalekan Akinyemi2Fatemeh Seilani3Md Rakibul Alam4Xiaoqi Liu5Department of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USAProstate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors such as Octamer Binding Factor 4 (OCT4)—plays a crucial role in therapeutic resistance and disease progression. OCT4, in coordination with SOX2 and NANOG, acts as a master regulator of stemness and is frequently upregulated in prostate cancer stem cells (PCSCs). This upregulation contributes to tumor initiation, metastasis, and resistance to both androgen deprivation therapy (ADT) and chemotherapy. In this review, we explore the role of OCT4 in mediating lineage plasticity in prostate cancer, with particular emphasis on its involvement in treatment resistance and neuroendocrine differentiation. We also examine therapeutic strategies aimed at targeting OCT4 directly, such as microRNA-mediated suppression, small-molecule inhibitors, and suicide gene therapy, as well as indirect approaches that modulate OCT4 expression via FGFR and NF-κB signaling pathways. While these strategies offer promising avenues, challenges such as adaptive resistance and the intricate signaling networks within PCSCs remain significant hurdles. A deeper understanding of the molecular mechanisms underlying OCT4-driven plasticity may pave the way for novel therapeutic approaches and improved outcomes in advanced prostate cancer.https://www.mdpi.com/2227-9059/13/7/1642octamer-binding transcription factor 4prostate cancer stem cellsandrogen deprivation therapycastration-resistant prostate cancerneuroendocrine prostate cancer
spellingShingle Mohammad Esfini Farahani
Yanquan Zhang
Amos Olalekan Akinyemi
Fatemeh Seilani
Md Rakibul Alam
Xiaoqi Liu
Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer
Biomedicines
octamer-binding transcription factor 4
prostate cancer stem cells
androgen deprivation therapy
castration-resistant prostate cancer
neuroendocrine prostate cancer
title Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer
title_full Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer
title_fullStr Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer
title_full_unstemmed Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer
title_short Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer
title_sort unlocking the role of oct4 in cancer lineage plasticity a cross cancer perspective with an emphasis on prostate cancer
topic octamer-binding transcription factor 4
prostate cancer stem cells
androgen deprivation therapy
castration-resistant prostate cancer
neuroendocrine prostate cancer
url https://www.mdpi.com/2227-9059/13/7/1642
work_keys_str_mv AT mohammadesfinifarahani unlockingtheroleofoct4incancerlineageplasticityacrosscancerperspectivewithanemphasisonprostatecancer
AT yanquanzhang unlockingtheroleofoct4incancerlineageplasticityacrosscancerperspectivewithanemphasisonprostatecancer
AT amosolalekanakinyemi unlockingtheroleofoct4incancerlineageplasticityacrosscancerperspectivewithanemphasisonprostatecancer
AT fatemehseilani unlockingtheroleofoct4incancerlineageplasticityacrosscancerperspectivewithanemphasisonprostatecancer
AT mdrakibulalam unlockingtheroleofoct4incancerlineageplasticityacrosscancerperspectivewithanemphasisonprostatecancer
AT xiaoqiliu unlockingtheroleofoct4incancerlineageplasticityacrosscancerperspectivewithanemphasisonprostatecancer